Jos Jonkers
Overview
Explore the profile of Jos Jonkers including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
246
Citations
17163
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moser S, Jonkers J
Cancer Discov
. 2025 Mar;
15(3):461-480.
PMID: 40025950
Here, we explore the impact of three decades of BRCA1 research on the lives of mutation carriers and propose strategies to improve the prevention and treatment of BRCA1-associated cancer.
2.
Khalizieva A, Moser S, Bouwman P, Jonkers J
Genes Dev
. 2024 Nov;
39(1-2):86-108.
PMID: 39510841
The discovery of and as tumor susceptibility genes and their role in genome maintenance has transformed our understanding of hereditary breast and ovarian cancer. This review traces the evolution of...
3.
Ciwinska M, Messal H, Hristova H, Lutz C, Bornes L, Chalkiadakis T, et al.
Nature
. 2024 Sep;
633(8028):198-206.
PMID: 39232148
Oncogenic mutations are abundant in the tissues of healthy individuals, but rarely form tumours. Yet, the underlying protection mechanisms are largely unknown. To resolve these mechanisms in mouse mammary tissue,...
4.
Heijmans N, Wiese K, Jonkers J, van Amerongen R
J Mammary Gland Biol Neoplasia
. 2024 Jun;
29(1):13.
PMID: 38916673
Conflicting data exist as to how mammary epithelial cell proliferation changes during the reproductive cycle. To study the effect of endogenous hormone fluctuations on gene expression in the mouse mammary...
5.
Nicotra R, Lutz C, Messal H, Jonkers J
J Mammary Gland Biol Neoplasia
. 2024 Jun;
29(1):12.
PMID: 38913216
Hormone receptor-positive (HR) breast cancer (BC) is the most common type of breast cancer among women worldwide, accounting for 70-80% of all invasive cases. Patients with HR BC are commonly...
6.
Dibitetto D, Liptay M, Vivalda F, Dogan H, Gogola E, Gonzalez Fernandez M, et al.
Nat Commun
. 2024 May;
15(1):4430.
PMID: 38789420
Histone H2AX plays a key role in DNA damage signalling in the surrounding regions of DNA double-strand breaks (DSBs). In response to DNA damage, H2AX becomes phosphorylated on serine residue...
7.
Hutten S, Messal H, Lips E, Sheinman M, Ciwinska M, Braams E, et al.
J Pathol
. 2024 May;
263(3):360-371.
PMID: 38779852
Mutations are abundantly present in tissues of healthy individuals, including the breast epithelium. Yet it remains unknown whether mutant cells directly induce lesion formation or first spread, leading to a...
8.
Inanc B, Fang Q, Andrews J, Zeng X, Clark J, Li J, et al.
bioRxiv
. 2024 Apr;
PMID: 38645048
The multitude of DNA lesion types, and the nuclear dynamic context in which they occur, present a challenge for genome integrity maintenance as this requires the engagement of different DNA...
9.
Derouane F, Desgres M, Moroni C, Ambroise J, Berliere M, Van Bockstal M, et al.
Breast Cancer Res
. 2024 Feb;
26(1):29.
PMID: 38374113
Background: Neoadjuvant chemotherapy (NAC) is the standard of care for patients with early-stage triple negative breast cancers (TNBC). However, more than half of TNBC patients do not achieve a pathological...
10.
Andronikou C, Burdova K, Dibitetto D, Lieftink C, Malzer E, Kuiken H, et al.
EMBO J
. 2024 Feb;
43(6):1015-1042.
PMID: 38360994
Targeting poly(ADP-ribose) glycohydrolase (PARG) is currently explored as a therapeutic approach to treat various cancer types, but we have a poor understanding of the specific genetic vulnerabilities that would make...